Fundamental Analysis of Verrica Pharmaceuticals Inc - Growth / Value Index


VRCA - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 8865.56 suggesting that it is very expensive
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -3665.46 -8136.92 -67169.01 %
Price to Book 8099.52 19891.67 268749 % 267.25
Price to Sales 33408.57 122696 374040 %
Enterprise Value to EBITDA Multiple -4.17 -8576.08 -70180.92 %


VRCA - Profitability Highlights

Profitability Analysis

   Excellent QoQ /QoQ FY EPS growth
   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 1.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   EPS decline for last four quarters
   Negative Net Margin MRQ
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -220.97 -244.46 -299.66 % -1348.21
Return On Asset -108.06 -59.21 -8.13 % -30.66
Net Profit Margin -911.44 -1507.90 -456.19 % -531.39
Operating Profit Margin -866.92 -1524.16 -546.42 % -486.12
EBITDA Margin -919.36 -1430.59 -501.29 % -486.12


Highlights
Market Cap367782 K
Enterprise Value341809 K
Price/Book TTM8099.52
Outstanding Share42420.10 K
Float/ Outstanding Share35.48%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score1.00
Altman Z Score-1.34
Sloan Ratio-0.236
Peter Lynch Fair Value0


VRCA - Growth Highlights

Growth Analysis

   YoY Net Margin Jump by 456.19%
   Quarterly sales in last 5 years is trending up
   Steady increase in Total Assets for last 3 Years
   Tsr Growth Index - Very Poor Score of 10.09
   Annual sales in last 3 years is trending down
   Companies' sales dropped by 64.53 % from last year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 8913.00 K 64.53 % 92.45 %
Gross Profit 8146.00 K 67.88 % 60.16 %
EBITDA -81943.00 K 113.30 % 33.12 %
Net Profit -81237.00 K 97.30 % 19.05 %
EPS -0.0024 99.85 % NA


VRCA - Stability Highlights

Stability Analysis

   Cash ratio of 4.09
   Tsr Stability Index - Very Poor Score of 5.00
   Altman Z Score of -1.01 suggest high risk
   Company has high debt burden
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -28.16
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 2.20 29619.14 % 29.08
Cash Ratio 4.09 -58.77 %
Quick Ratio 4.49 -60.75 % 3.04
Shareholders Equity 24.22 -72.94 %
Debt to EBITDA -0.951 -6778.29 %


Historical Valuation Ratios of Verrica Pharmaceuticals Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Verrica Pharmaceuticals Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Verrica Pharmaceuticals Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Verrica Pharmaceuticals Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)